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http://dx.doi.org/10.1016/j.ccr.2012.06.028SUMMARYThe success of chemotherapy in cancer treatment is limited by scarce drug delivery to the tumor and severe
side-toxicity. Prolyl hydroxylase domain protein 2 (PHD2) is an oxygen/redox-sensitive enzyme that induces
cellular adaptations to stress conditions. Reduced activity of PHD2 in endothelial cells normalizes tumor
vessels and enhances perfusion. Here, we show that tumor vessel normalization by genetic inactivation of
Phd2 increases the delivery of chemotherapeutics to the tumor and, hence, their antitumor and antimeta-
static effect, regardless of combined inhibition ofPhd2 in cancer cells. In response to chemotherapy-induced
oxidative stress, pharmacological inhibition or genetic inactivation of Phd2 enhances a hypoxia-inducible
transcription factor (HIF)-mediated detoxification program in healthy organs, which prevents oxidative
damage, organ failure, and tissue demise. Altogether, our study discloses alternative strategies for chemo-
therapy optimization.INTRODUCTION
Part of the failure that still escorts cancer treatment is due to the
abnormal tumor vasculature, characterized by leaky, tortuous,
and fragile vessels; loss of hierarchical architecture; and an
abnormal endothelial layer. The resultant hypoxia promotes
invasion and metastasis (Carmeliet and Jain, 2011). In addition,Significance
Chemotherapy remains the most common treatment option fo
severe side effects impede delivery of chemotherapeutic drug
antiangiogenic strategies can worsen this situation by hinderin
we identify PHD2 as amolecular target to enhance chemothera
to counter chemotherapy-induced side effects via a HIF-medi
role of PHD2 as gatekeeper for oxidative stress, and they war
association with chemotherapy. Taken together, our study off
cancer therapy.hypoperfused vessels and increased interstitial tumor pressure
impede the delivery of anticancer drugs to the tumors and thus
limit their efficacy (Carmeliet and Jain, 2011).
To date, anti-vascular endothelial growth factor and anti-vas-
cular endothelial growth factor receptor [VEGF(R)] approaches
have therefore gained interest as a therapeutic option to improve
drug delivery and the overall response to anticancer treatment,r cancer patients. However, dysfunctional blood vessels and
s to the tumor, thus limiting their use in the clinic. Traditional
g tumor perfusion and exacerbating adverse reactions. Here,
peutic drug delivery to the tumor via vessel normalization and
ated detoxification response. These data unveil an essential
rant caution for considerate use of HIF blockers in cancer in
ers the rationale for developing PHD2 specific inhibitors for
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Figure 1. Stromal Phd2 Haplodeficiency Enhances Tumor Response to Chemotherapy
(A) Platinum levels (as readout of cisplatin, CPt) in tumors and healthy organs (kidney and liver) of WT and Phd2+/ mice (n = 4–5).
(B and C) Quantification (B) and representative images (C) showing increased intratumoral CPt DNA-adducts in Phd2+/ mice (n = 3).
(D) Interstitial fluid pressure of LLC tumors is decreased in Phd2+/ mice (n = 6–7).
(E–H) Reduced growth and weight of B16 melanoma tumors (E and F) or LLC tumors (G and H) in Phd2+/mice upon suboptimal doses (2.5 mg/kg; 33 per week)
of CPt or doxorubicin (DOX), respectively (n = 5–9).
(I) Number of lung metastatic nodules in LLC tumor-bearing mice (n = 5–6).
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Phd2 Targeting Optimizes Chemotherapygiven their ability to promote tumor vessel normalization in
preclinical and clinical studies (Carmeliet and Jain, 2011; Goel
et al., 2011). Nonetheless, this concept has been recently chal-
lenged by the observation that bevacizumab, a humanized
monoclonal antibody that blocks VEGF, reduces both perfusion
and tumor drug uptake in non-small cell lung cancer patients
(Van der Veldt et al., 2012). Importantly, current antiangiogenic
therapies are more toxic than anticipated, particularly when
used in combination with chemotherapeutic drugs (D’Adamo
et al., 2005). Alternative approaches have been evaluated in
preclinical tumormodels in order to increase the local concentra-
tion of chemotherapeutics, either by normalizing tumor blood
flow (Fischer et al., 2007; Rolny et al., 2011; Stockmann et al.,
2008) or by using tumor specific deliveries (Dhar et al., 2011;
Jain, 2010). However, so far, none of the strategies tested show
efficient drug delivery to the tumor and simultaneous protection
of vital organs, thus optimizing the cytostatic efficiency of the
drug and preventing undesired, life-threatening toxic effects.
Prolyl hydroxylase domain proteins (PHD1-3) are enzymes
that utilize oxygen to hydroxylate and target the alpha sub-
unit of the hypoxia-inducible transcription factors HIF-1 and
HIF-2 for proteasomal degradation (Epstein et al., 2001). When
oxygen tension drops, PHDs become less active, leading to
hypoxia-inducible transcription factor (HIF) stabilization and,
consequently, to the initiation of an adaptive response, including
angiogenesis, metabolic reprogramming, erythropoiesis, and
scavenging of reactive oxygen species (ROS) (Aragone´s et al.,
2008; Lee et al., 1997; Mukhopadhyay et al., 2000; Scortegagna
et al., 2003). By using cancer as a model of abnormal angiogen-
esis, we recently showed that heterozygous deficiency of Phd2
(also known as Egln1) in endothelial cells (EC) does not affect
vessel density or lumen size, but normalizes their endothelial
lining, barrier, stability, and pericyte coverage, at least in part,
via HIF-2-mediated upregulation of the adherens junction vas-
cular endothelial-cadherin and the soluble VEGF trap sFlt1.
This change in vessel structure and endothelial shape improves
tumor perfusion and oxygenation and, hence, inhibits cancer cell
intravasation and metastasis (Mazzone et al., 2009). Moreover,
gene deletion or knockdown of Phd1 confers tissue protection
against ischemia/reperfusion-induced oxidative damage (Ara-
gone´s et al., 2008; Schneider et al., 2010); conversely, reduced
activity of HIF-1 or HIF-2 has been associated to increased
ROS production and, thereby, tissue dysfunction in both normal
and stress conditions (Lee et al., 1997; Mukhopadhyay et al.,
2000; Scortegagna et al., 2003). This has critical implications in
cancer therapy, since both chemotherapeutic- and irradiation-
based treatments generate ROS that impair normal organ func-
tion and cause tissue demise (Anscher et al., 2005; Berthiaume
and Wallace, 2007; Pabla and Dong, 2008).
In the present study, we investigate the biological and thera-
peutic relevance of gene-targeting the oxygen/redox-sensitive(J and K) Representative micrographs (J) andmorphometric quantification (K) of h
area (yellow dashed line) in Phd2+/ LLC tumor-bearing mice and no metastases
(L) Metastatic incidence in LLC tumor-bearing mice (n = 5–6).
(M and N) LLC tumor growth in response to suboptimal doses of DOX (2.5 mg
Tie2;Phd2+/+mice transplantedwithWT bonemarrow,WT/ Tie2;Phd2L/+ andW
to ensure that Phd2 is not deleted in the hematopoietic compartment, where the
*p < 0.05 versus WT, #p < 0.05 versus saline. Scale bars denote 20 mm in (C) andenzyme PHD2 in different cell compartments on the tumor
response to chemotherapy. At the same time,wepursue amech-
anistic understanding on how pharmacological and genetic inhi-
bition of PHD2 affects chemotherapy-associated ROS produc-
tion in healthy organs and, subsequently, tissue damage and
function.
RESULTS
Stromal Loss of Phd2 Sensitizes the Tumor to
Chemotherapy
We recently showed that endothelial haplodeficiency of Phd2
(Phd2+/) streamlines the tumor vasculature (Mazzone et al.,
2009). Prompted by these results, we examined whether partial
loss of Phd2 also enhances the delivery of chemotherapeutic
drugs. We therefore subjected wild-type (WT) and Phd2+/
mice carrying equal-size B16 melanomas to a single dose of
cisplatin (20 mg/kg) and measured platinum accumulation in
tumor, kidney, and liver 1 hr after drug injection. While normal
organs showed similar cisplatin concentrations in both WT and
Phd2+/ mice (Figure 1A), intratumoral platinum and drug diffu-
sion out of the tumor vessels was higher in Phd2+/ than in WT
mice (Figures 1A–1C), the latter being consistent with a reduction
of tumor interstitial fluid pressure (Figure 1D), a physical param-
eter hindering efficient transit of drugs within the tumor (Heldin
et al., 2004).
To assess whether the improved drug delivery translated
into enhanced antitumor effects, we treated B16 tumor-bearing
mice with a suboptimal dose of cisplatin (2.5 mg/kg; 33 per
week), which did not have any therapeutic effect in WT mice
(Figures 1E and 1F). In contrast, end-stage tumor volume and
tumor weight were reduced in Phd2+/ mice by more than
70% (Figures 1E and 1F). We then extended our study to
a different tumor histotype, i.e., Lewis lung adenocarcinoma
(LLC), which was treated with doxorubicin. A suboptimal dose
of doxorubicin (2.5 mg/kg; 33 per week) did not affect the
growth of subcutaneously implanted LLC tumors in WT mice,
whereas it reduced end-stage volume and weight by about
60% in Phd2+/ mice (Figures 1G and 1H). As previously shown
(Mazzone et al., 2009), number, area, and incidence of pulmo-
nary metastasis were reduced in Phd2+/ versus WT untreated
mice (Figures 1I–1L). Doxorubicin treatment did not affect meta-
static burden in WT mice, while it completely prevented metas-
tasis formation in Phd2+/mice, likely due to the strong inhibition
of primary tumor growth (Figures 1G–1L). Deletion of one Phd2
allele in EC, but not in myeloid cells or in fibroblasts, induced
chemosensitization of LLC tumors to a suboptimal dose of doxo-
rubicin (Figures 1M and 1N; Figures S1A and S1B available
online).
In B16 tumors, suboptimal doses of cisplatin promoted tumor
cell apoptosis and reduced proliferation in Phd2+/mice (Figuresematoxylin and eosin (H&E)-stained lung sections revealing reducedmetastatic
in Phd2+/ mice treated with DOX (n = 5–6).
/kg; 33 per week) in Tie2;Phd2L/+ mice (M; n = 6–9) or in Tie2;Phd2L/+ and
T/ Tie2;Phd2+/+, respectively (N; n = 5–9). The bonemarrow transplantation is
Tie2Cre deleter is also active.
200 mm in (J). All graphs show mean ± SEM. See also Figure S1.
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Phd2 Targeting Optimizes Chemotherapy2A–2F and Table S1). In doxorubicin-treated LLC tumors, apo-
ptosis, but not proliferation, was higher in Phd2+/ versus WT
mice (Figures 2G and 2H and Table S1). Tumor apoptosis and
proliferation did not change in WT and Phd2+/ untreated mice
(Figures 2B, 2C, and 2E–2H and Table S1).
Cytostatic drugs can display some antiangiogenic effects
(Kerbel andKamen, 2004). However, baseline and posttreatment
tumor vessel perfusion and oxygenationwere comparably higher
in Phd2+/ versus WT mice, despite similar vessel density and
area (Figures 2I–2N). Similarly, endothelial Phd2 haplodeficiency
increased tumor perfusion in both doxorubicin-treated and
untreated mice (Figure S2).
Altogether, these data show that reduction of Phd2 in EC
enhances the response of the tumor to chemotherapy by in-
creasing vessel perfusion and drug delivery.
Acute Loss of One or Two Phd2 Alleles Enhances
Chemotherapy
The above findings show that constitutive deletion of Phd2 in
EC induces tumor vessel normalization and thus increases
tumor response to chemotherapeutics. To assess the effect of
inducible deletion of Phd2 on chemoresponse, we intercrossed
Phd2-floxed mice with the tamoxifen-inducible Rosa26CreERT2
mouse strain, where the Rosa26 (R26) promoter directs the
ubiquitous expression of the fusion protein Cre-ERT2. We also
exploited this system to compare the effect of heterozygous
(R26;Phd2L/+) versus homozygous (R26;Phd2L/L) deletion, lead-
ing, respectively, to about 50% and 2%–5% of the PHD2 pro-
tein levels in different tissues of WT (R26;Phd2+/+) mice (Figures
3A and S3A and Table S2). In vitro, primary EC isolated from
R26;Phd2L/+ and R26;Phd2L/L mice displayed increasing accu-
mulation of HIF-1a (Figure 3A and Table S2). Conversely, HIF-
2a was higher, but elevated to the same level in both
R26;Phd2L/+ and R26;Phd2L/L primary EC, likely due to compen-
satory mechanisms promoted by induction of Phd3 (Figures 3A
and S3B and Table S2).
In vivo, deletion of one or two Phd2 alleles in stromal
cells (achieved by tamoxifen administration for 5 consecutive
days following LLC cell injection) did not alter tumor growth
in untreated mice, but was equally potent in sensitizing the
tumor to the effect of doxorubicin (Figures 3B and 3C). Meta-
static dissemination was almost completely prevented in both
R26;Phd2L/+ andR26;Phd2L/Lmice after doxorubicin (Figure 3D).
Features of tumor vessel normalization, as vessel coverage
(Figures 3E and 3F), vessel perfusion (Figures 3G and S3C), and
tumor oxygenation (Figure 3H), were promoted in both doxoru-
bicin-treated and untreated R26;Phd2L/+ and R26;Phd2L/L mice.
Vegf is an oxygen-sensitive gene that is strongly expressed by
the tumor in response to hypoxia as well as oncogenic activation
(Semenza, 2003). Previous reports have shown that systemic
levels of VEGF following postnatal deletion of Phd2 increase or
can remain unchanged, depending on the experimental settings
(Minamishima et al., 2008; Takeda et al., 2007). Thirty days after
genetic deletion of Phd2 (i.e., about the duration of our tumor
experiments), plasma levels of VEGF were slightly increased by
12% and 29%, respectively, in R26;Phd2L/+ and R26;Phd2L/L
tumor-free mice (Figure 3I). In tumor-bearing mice, as expected,
VEGF levels were generally higher, but in both R26;Phd2L/+ and
R26;Phd2L/L tumor-bearing mice, these levels were lower than in266 Cancer Cell 22, 263–277, August 14, 2012 ª2012 Elsevier Inc.R26;Phd2+/+ tumor-bearing mice, because vessel normalization
and improved oxygenation partly prevented VEGF production by
the tumor itself (Figures 3I and 3J).
The effect of Phd2 knockdown in cancer cells depends on the
tumor histotype (Ameln et al., 2011; Andersen et al., 2011; Bor-
doli et al., 2011; Chan et al., 2009; Kamphues et al., 2012; Lee
et al., 2008; Peurala et al., 2012; Su et al., 2012), while our data
show a better disease outcome when the tumor stroma is insuf-
ficient for Phd2. To assess the effect of combined Phd2 inactiva-
tion in cancer cells and stromal cells, we subcutaneously in-
jected scramble and Phd2-silenced LLC cells in R26;Phd2+/+
and R26;Phd2L/+ mice. The efficiency of PHD2 silencing was
65% on both RNA and protein levels (Figure S3D). In vitro,
hypoxia, but not Phd2 silencing, enhanced the expression of
VEGF (Figure S3E). In vivo, due to vessel normalization and the
subsequent decrease in tumor hypoxia, intratumoral VEGF in
R26;Phd2L/+ mice was lower than in R26;Phd2+/+ mice, regard-
less of Phd2 silencing in cancer cells (Figures 3K and S3F).
Following doxorubicin treatment, the chemoresponse of both
scramble and Phd2-silenced LLC tumors was equally improved
in R26;Phd2L/+ mice (Figure 3L).
These data suggest that systemic inhibition of PHD2 might
offer a therapeutic benefit.
Loss of Phd2 Protects Normal Organs against
Side-Toxicity of Chemotherapy
Side-toxicity limits the clinical use of chemotherapeutic drugs.
Thus, we wanted to assess the effect of cisplatin and doxoru-
bicin on WT and Phd2+/ kidneys and hearts, respective target
organs for drug toxicity. Three days after acute cisplatin admin-
istration (20 mg/kg), blood urea and creatinine were 7.9- and
21.9-fold increased inWTmice, but only 4.7 and 4.3 times higher
in Phd2+/ mice (Figure 4A). Histological inspection of periodic
acid-Schiff (PAS)-stained kidney sections from WT mice re-
vealed severe proximal tubular necrosis and dilatation with
formation of protein casts into the lumen, overt destruction of
the brush border, and consequent deformations/atrophy of the
glomerular structures (Figure 4B). In contrast, the histological
morphology of Phd2+/ kidneys was preserved and more com-
parable to the one of untreated kidneys (Figures 4B and S4A).
Transcript levels of kidney injury molecule 1 (Kim1) and protein
levels of the apoptotic marker-cleaved caspase-3 were strongly
induced by cisplatin in WT, but barely in Phd2+/ kidneys
(Figures 4C and 4D and Table S3). Consistently, the mean
survival after cisplatin was 7 days in Phd2+/ mice, while only
3 days in WT mice (Figure 4E). Upon chronic administration of
cisplatin (2.5 mg/kg; 33 per week), only urea, but not creatinine,
rose to indicative levels of nephrotoxicity in WT mice, while
Phd2+/ mice showed great protection (Figure S4B).
Similarly, WT and Phd2+/ mice were treated with an acute
dose of doxorubicin (20 mg/kg). Five days after drug administra-
tion, doxorubicin reduced cardiac output by 22.3% in WT mice,
while it did not display any effect in Phd2+/ mice (Figure 5A).
In doxorubicin-treated WT mice, histological analysis of heart
sections revealed disarray and vacuolization of myofibers with
excessive collagen deposition, all histopathological signs of
cardiomyopathy (Figures 5B and 5C). In Phd2+/ hearts, these
features were milder and rarely observed, overall resembling
the structure of untreated hearts (Figures 5B and S5A). Creatine
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Figure 2. Histological Analysis of Tumors in Phd2+/– Mice after Chemotherapy
(A and B) Cleaved caspase-3 staining (A) and morphometric quantification (B) on B16 tumor sections, showing increased tumor apoptosis in Phd2+/mice after
CPt (n = 5–6).
(C) Immunoblot for cleaved and total caspase-3, revealing increased tumor apoptosis in Phd2+/ mice after CPt (n = 3).
(D and E) Phosphohistone H3 staining (D) and morphometric quantification (E) on B16 tumor sections, showing reduced tumor cell proliferation in Phd2+/mice
after CPt (n = 5–6).
(F) Immunoblot for the proliferation marker Cdc2 on untreated and Cpt-treated B16 tumors; tubulin is used as loading control (n = 3).
(G and H) Immunoblot for cleaved caspase-3 (G) and Cdc2 (H) on untreated and DOX-treated LLC tumors (n = 3).
(I and J) Vessel density (I) and vessel area (J) of LLC tumors (n = 6–10).
(K and L) Representative micrographs (K) and morphometric quantification (L) of LLC tumor sections stained for the endothelial marker CD31 (red) and for
intravenously injected lectin (green), showing higher vessel perfusion in both untreated and DOX-treated Phd2+/ mice (n = 7–9).
(M and N) Pimonidazole (PIMO) staining (M) and morphometric quantification (N) on LLC tumor sections, showing reduced tumor hypoxia in both untreated and
DOX-treated Phd2+/ mice (n = 7–9).
*p < 0.05 versus WT; #p < 0.05 versus saline. Scale bars denote 100 mm in (A), (K), and (M) and 20 mm in (D). All graphs showmean ± SEM. See also Figure S2 and
Table S1.
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Figure 3. Acute Loss of Phd2 Enhances Tumor Response to Chemotherapy
(A) Immunoblot for HIF-1a and HIF-2a in WT (R26;Phd2+/+), Phd2 haplodeficient (R26;Phd2L/+), and Phd2 null (R26;Phd2L/L) endothelial cells (EC).
(B and C) Reduced LLC tumor growth (B) and weight (C) following DOX (2.5 mg/kg, 33 per week) upon tamoxifen-induced deletion of one (R26;Phd2L/+) or two
(R26;Phd2L/L) Phd2 alleles (n = 10–12; *p < 0.05).
(D) Metastasis inhibition in R26;Phd2L/+ and R26;Phd2L/L LLC tumor-bearing mice; lung metastatic nodules were further reduced upon DOX (n = 10–12).
(E and F) Quantification (E) and staining (F) for CD34 (green) and alpha-smooth muscle actin (SMA) (red), revealing increased pericyte coverage of tumor vessels in
untreated and DOX-treated R26;Phd2L/+ and R26;Phd2L/L mice. Higher magnification images are shown as insets (n = 6–8).
(G andH)Morphometric quantification of LLC tumor sections stained for the endothelial marker CD31 and intravenously injected 2MDa dextran-FITC (G) or PIMO
(H), showing, respectively, increased tumor vessel perfusion or reduced tumor hypoxia in both untreated and DOX-treated R26;Phd2L/+ and R26;Phd2L/L mice
(n = 10–12 or n = 4–6, respectively).
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Figure 4. Phd2 Loss Protects against
Cisplatin-Induced Nephrotoxicity
(A) Reduced plasma urea and creatinine inPhd2+/
mice 72 hr post-CPt injection (20 mg/kg; n = 6–10).
(B) PAS staining on kidney sections from CPt-
treated mice, revealing severe tubular dilation,
protein cast (white asterisks), and detachment of
atrophic glomeruli (white arrow) in WT, but not in
Phd2+/ mice.
(C) RNA levels of kidney injury molecule 1 (Kim1)
after CPt (n = 6–10).
(D) Immunoblot for cleaved caspase-3 on kidneys
showing protection in Phd2+/ mice against CPt-
induced apoptosis.
(E) Kaplan-Meier survival curve, illustrating in-
creased survival of Phd2+/ mice upon acute
administration of CPt.
(F) Reduced plasma urea and creatinine levels in
CPt-treated R26;Phd2L/+ and R26;Phd2L/L mice
(n = 5–7; #p < 0.05 versus baseline R26;Phd2+/+;
xp < 0.05 versus R26;Phd2+/+ CPt).
Unless otherwise denoted: *p < 0.05 versus WT,
#p < 0.05 versus baseline. Scale bars denote
40 mm in (B). All graphs show mean ± SEM. See
also Figure S4 and Table S3.
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Phd2 Targeting Optimizes Chemotherapykinase (CK), released in the plasma upon acute cardiac injury,
was strongly elevated in WT mice, but 2-fold lower in Phd2+/
mice (Figure 5D). Myocardial death following doxorubicin admin-
istration was completely prevented in Phd2+/ mice (Figure 5E
and Table S4). Consistently, the mean survival after doxorubicin
was 20 days in Phd2+/mice, while only 5 days in WT mice (Fig-
ure 5F). A chronic regimen of doxorubicin as well (2.5 mg/kg; 33
per week) preserved cardiac ejection fraction in Phd2+/ mice
(Figure 5G). Gene expression of brain natriuretic peptide (Bnp),(I) Plasma VEGF levels quantified by ELISA in R26;Phd2+/+, R26;Phd2L/+, and R26;Phd2L/L LLC tumor-free a
versus R26;Phd2+/+ tumor-free).
(J) Intratumoral VEGF levels are decreased in R26;Phd2L/+ and R26;Phd2L/L mice (n = 6–8).
(K) Intratumoral VEGF levels are decreased in R26;Phd2L/+ mice, regardless of Phd2 silencing in cancer cell
(L) Combined inactivation of Phd2 in both stroma (R26;Phd2+/+ and R26;Phd2L/+mice) and cancer cells (shPh
(2.5 mg/kg, 33 per week) (n = 8–10; *p < 0.05).
Unless otherwise denoted: *p < 0.05 versus R26;Phd2+/+ saline, #p < 0.05 versus saline, xp < 0.05 versus R2
graphs show mean ± SEM. See also Figure S3 and Table S2.
Cancer Cell 22, 263–277a marker of chronic heart toxicity, was
35.2% lower in Phd2+/ than WT mice
after doxorubicin (Figure 5H).
The protection of healthy organs
against chemotherapy can be mainly
ascribed to reduced activity of PHD2 in
tissue cells, since heterozygous deletion
of Phd2 in EC (and infiltrating leukocytes)
did not prevent side-toxicity of cisplatin
and doxorubicin (Figures S4C and S5B).
We then assessed the effect of acute
deletion of one versus two Phd2 alleles.
To this end, R26;Phd2L/+, R26;Phd2L/L,
andR26;Phd2+/+ control mice, pretreated
with tamoxifen for 5 days, were injectedwith an acute dose of cisplatin (20 mg/kg) or doxorubicin
(20 mg/kg). Both heterozygous and homozygous deletion of
Phd2 were equally able to prevent renal and cardiac damage,
as assessed by lower concentrations of plasma urea, creatinine,
and CK in R26;Phd2L/+ and R26;Phd2+/+ mice after drug admin-
istration (Figures 4F and 5I).
Altogether, these results indicate that genetic inactivation of
Phd2 confers protection against chemotherapy-associated
nephropathy and cardiomyopathy.s well as tumor-bearing mice (n = 5–10; #p < 0.05
s (n = 8–10; *p < 0.05).
d2) equally enhances LLC tumor response to DOX
6;Phd2+/+ DOX. Scale bars denote 50 mm in (F). All
, August 14, 2012 ª2012 Elsevier Inc. 269
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Figure 5. Phd2 Loss Protects against Doxo-
rubicin-Induced Cardiotoxicity
(A) B-mode measurement of left ventricular func-
tion, revealing unaltered ejection fraction in
Phd2+/ mice 5 days after acute administration of
DOX (20 mg/kg; n = 7–11).
(B) H&E-staining on DOX-treated heart sections
reveals extensive cytoplasmic vacuolization (white
arrow), myofibrillar loss, and cell death (white
asterisks) in WT, but not in Phd2+/ mice.
(C) Sirius red staining on DOX-treated heart
sections identifies extensive fibrotic areas in WT,
but not in Phd2+/ mice.
(D) Increased plasma creatine kinase (CK) by DOX
is prevented in Phd2+/ mice (n = 5–7).
(E) Immunoblot for cleaved caspase-3 on hearts
showing prevention of DOX-induced apoptotis in
Phd2+/ mice.
(F) Kaplan-Meier curve, illustrating increased
survival of Phd2+/ mice upon acute administra-
tion of DOX (n = 7–8; *p < 0.001 versus WT).
(G) B-mode measurement of left ventricular func-
tion in Phd2+/ andWTmice 1 month after chronic
treatment (2.5 mg/kg; 33 per week) with DOX (n =
30; *p < 0.001; #p < 0.001 versus baseline).
(H) RNA levels of brain natriuretic peptide (Bnp)
in heart after chronic administration of DOX (n =
9–11).
(I) Plasma CK values upon acute DOX treatment in
tamoxifen-treated in R26;Phd2+/+, R26;Phd2L/+,
and R26;Phd2L/L mice (n = 5–7; #p < 0.05
versus baseline R26;Phd2+/+; xp < 0.05 versus
R26;Phd2+/+ DOX).
Unless otherwise denoted: *p < 0.05 versus WT,
#p < 0.05 versus baseline. Scale bars denote
20 mm in (B) and (C). All graphs showmean ± SEM.
See also Figure S5 and Table S4.
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Phd2 Targeting Optimizes ChemotherapyLoss of Phd2 Mounts an Antioxidative Response in
Normal Organs
The toxicity of cisplatin and doxorubicin on quiescent and
healthy organs has been, in part, ascribed to oxidative stress
formation (Berthiaume and Wallace, 2007; Pabla and Dong,
2008). We therefore assessed the burst of ROS after chemo-
therapy by staining kidney and heart sections for 8-hydroxy de-
oxyguanosine (8-OHdG), a marker of oxidative DNA damage.
Acute cisplatin administration raised the number of 8-OHdG+
nuclei in WT kidneys to 52.3%, while only to 35% in Phd2+/
kidneys (Figures 6A and 6B). 8-OHdG+ nuclei were undetectable270 Cancer Cell 22, 263–277, August 14, 2012 ª2012 Elsevier Inc.at baseline in both genotypes (Fig-
ure S6A). Similarly, both acute and
chronic administration of doxorubicin re-
sulted in reduced oxidative damage in
Phd2+/ versus WT hearts (Figures 6C–
6E). 8-OHdG+ nuclei in baseline hearts
were similar in both genotypes (Figures
S6B and S6C). When treated with acute
regimens of doxorubicin or cisplatin,
RNA, protein levels, and activity of
primary antioxidative enzymes (AOE),
such as superoxide dismutase 1 (Sod1),
superoxide dismutase 2 (Sod2), catalase(Cat), and glutathione peroxidase 1 (Gpx1), were significantly
higher in Phd2+/ than in WT organs (Figures 6F–6H and Tables
S5 and S6). Baseline levels and activity of these enzymes
were similar in both genotypes (not shown). Administration
of the ROS scavenger Mn(III)tetrakis(4-benzoic acid)porphyrin
(MnTBAP) greatly prevented the induction of AOE in Phd2+/
hearts after doxorubicin, indicating that ROS production by
chemotherapy is necessary to trigger this detoxification re-
sponse (Figure 6I). Pharmacological inhibition of these AOE in
combination with doxorubicin completely abrogated the cardiac
protection conferred by loss of Phd2 (Figure 6J).
Cancer Cell
Phd2 Targeting Optimizes ChemotherapyWe then assessed whether the nonspecific prolyl hydroxylase
inhibitor dimethyloxaloylglycine (DMOG) could offer a similar
cardiac protection as genetic inactivation of Phd2. When mea-
suring plasma CK as readout of toxicity, DMOG-treated WT
mice displayed a 53% reduction of CK release after doxorubicin
(Figure 6K). From a molecular point of view, DMOG alone did
not induce AOE upregulation, in line with our observations in
Phd2+/ mice at baseline. However, the combination of DMOG
and doxorubicin enhanced the expression of Cat, Sod1, Sod2,
and Gpx1, consistent with the fact that an oxidative challenge
is required to initiate the detoxification response (Figure 6L).
We also evaluated the biological consequences of reduced
PHD2 activity on ROS homeostasis in LLC cancer cells, where
the cytostatic effect of these drugs is primarily linked to cell
proliferation (not shown). Silencing of Phd2 did not affect the
expression of AOE either in vitro or in vivo: neither did it
affect ROS induction (Figures S6D–S6G). Consistently, in vitro
cell death in response to doxorubicin was comparable in both
scramble and Phd2-silenced LLC (Figure S6H).
Thus, a reduction of PHD2 triggers effective antioxidative
responses in normal organs, but not in tumors, in response to
chemotherapy.
TheAntioxidative Response by Loss ofPhd2 Is HIF-1 and
HIF-2 Dependent
The AOE upregulated in Phd2+/ organs are HIF downstream
targets (Scortegagna et al., 2003). To assess HIF transcriptional
activity in WT and Phd2+/ hearts at baseline and after doxoru-
bicin, we used an adenoassociated virus serotype-9 (AAV9)
carrying a HIF-responsive firefly luciferase reporter (Figure 7A).
HIF activity was comparable in both genotypes at baseline.
However, 24 hr after doxorubicin administration, HIF activity
was 5.4 times higher in WT hearts, but 9.8 times higher in
Phd2+/ hearts (Figure 7A). This effect was specific and not
secondary to hypoxia, since the constitutive cytomegalovirus
(CMV) promoter was not differentially regulated and we were
not able to detect any hypoxic regions in response to doxoru-
bicin (Figure S7A and not shown). Similar results were obtained
in kidneys, where HIF activity 24 hr after a bolus of cisplatin
was 8.1-fold increased in WT mice, but 13.5-fold increased in
Phd2+/ mice (Figure 7B).
To assess the contribution of HIF-1a versus HIF-2a, we inter-
crossed Phd2+/ mice with Hif1a+/ or Hif2a+/ mice, displaying
about 50% reduction in Hif1a or Hif2a, respectively (Figures S7B
and S7C). Heterozygous deficiency of either Hif1a or Hif2a in
Phd2+/ mice abrogated the upregulation of Sod1, Sod2, Cat,
and Gpx1 after doxorubicin (Figures 7C and 7D). In vitro, both
HIF-1a and HIF-2a were more abundant in Phd2+/ cardiomyo-
cytes compared to WT and accumulated to even higher levels
in Phd2/ cardiomyocytes (Figure 7E and Table S7). In re-
sponse to doxorubicin, both HIFs were slightly higher in WT car-
diomyocytes, but they were more potently induced in Phd2+/
and in Phd2/ cells up to comparable levels (Figure 7E and
Table S7).
In order to block simultaneously HIF-1 and HIF-2, we treated
WT and Phd2+/mice with chetomin, which disrupts the interac-
tion of the transcriptional coactivator p300with the alpha subunit
of HIF (Kung et al., 2004). Administration of chetomin prevented
the induction of Sod1, Sod2, Cat, and Gpx1 and completelyabrogated the protection against oxidative stress and tissue
damage conferred by Phd2 haplodeficiency in response to
doxorubicin (Figures 8A–8C), supporting that both HIFs are
responsible for the chemoprotection in Phd2+/ mice.
DISCUSSION
During the last decade, much progress has been made in
increasing the arsenal and selectivity of anticancer drugs.
However, side effects and resistance to therapy still remain
major issues (Berthiaume and Wallace, 2007; Pabla and Dong,
2008). Based on previous research (Mazzone et al., 2009), we
now describe PHD2 as a potential and promising target, not
only to improve delivery of cytotoxic drugs selectively to the
tumor, but also to protect normal organ functions from side-
toxicity of chemotherapy. From a biological point of view, two
distinct mechanisms underlie these different phenomena. In
tumors, on one hand, we show that acute deletion of one or
two Phd2 alleles in stromal cells increases tumor vessel perfu-
sion and thus allows doxorubicin and cisplatin to better reach
the tumor, regardless of Phd2 targeting in cancer cells. Together
with the inhibition of metastasis, PHD2 inactivation provides
a potent antitumor effect when combined with conventional
chemotherapeutic regimens (Figure 8D, left panel). In healthy
organs, on the other hand, reduced activity of PHD2 in hearts
and kidneys amplifies the antioxidative response and thus
counters the oxidative burst and subsequent tissue damage
caused by doxorubicin and cisplatin (Figure 8D, right panel).
Previous studies have shown that VEGF(R) blockade
promotes a transient window of tumor vessel normalization in
which the chemo- and radio-response of the tumor is enhanced
(Goel et al., 2011; Winkler et al., 2004). Beyond this ‘‘normaliza-
tion window,’’ VEGF blockade leads to vessel pruning, which
might increase hypoxia and fuel a shift to malignancy, together
with an overall reduction of drug delivery and tumor uptake
(Loges et al., 2009). In addition, resistance mechanisms are
evoked by the antiangiogenic treatment itself (Loges et al.,
2009). By using different genetic tools, we show that reduced
activity of PHD2 in EC normalizes the tumor vasculature, not
vessel numbers, and increases drug efficiency. This effect is
similar and preserved until the end stage of the disease if Phd2
is inactivated either before or after tumor onset or following
systemic inactivation of one or two Phd2 alleles. Moreover,
chemotherapeutic drugs in Phd2+/ mice have a synergic effect
on metastasis inhibition. Finally, Phd2+/ vessels have im-
proved functionality prior to and postchemotherapy, altogether
suggesting the absence of resistance modes. Nevertheless,
we cannot formally exclude that PHD2 might affect tumor-
stromal interactions that confer protection on cancer cells from
the cytotoxic effect of anticancer agents (Provenzano et al.,
2012; Nakasone et al., 2012). A deletion of Phd2 in the host
stroma may alter its interactions with cancer cells, resulting in
an unfavorable microenvironment that could render tumor cells
more sensitive to drug treatment.
Phd2 silencing in cancer cells can display both a pro-
and antitumoral effect, depending on the cellular context
(Ameln et al., 2011; Andersen et al., 2011; Bordoli et al., 2011;
Chan et al., 2009; Kamphues et al., 2012; Lee et al., 2008; Peur-
ala et al., 2012; Su et al., 2012). However, there are more tumorCancer Cell 22, 263–277, August 14, 2012 ª2012 Elsevier Inc. 271
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Figure 6. Phd2 Loss Favors an Antioxidative Response in Normal Organs
(A–D) Representative micrographs (A,C) and morphometric quantification (B,D) of 8-hydroxy deoxyguanosine (8-OHdG; red) positive nuclei in kidney sections
72 hr after acute administration of CPt (20 mg/kg) or in heart sections 5 days after acute administration of DOX (20 mg/kg), respectively; DAPI (blue) was used for
nuclear localization (n = 5).
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Figure 7. Chemoprotection of Normal Organs by Phd2 Loss Requires HIF-1 and HIF-2
(A and B) HIF-reporter luciferase assay, showing enhanced HIF activity upon chemotherapy in Phd2+/ hearts (A) and kidneys (B) (n = 4).
(C and D) Either Hif1a (C) or Hif2a (D) heterozygosity prevents the transcriptional induction of AOE in Phd2+/ mice upon DOX treatment (n = 5–10).
(E) Immunoblot for HIF-1a and HIF-2a in untreated and DOX-treated WT, Phd2+/, and Phd2/ cardiomyocytes.
*p < 0.05 versus WT, #p < 0.05 versus baseline, xp < 0.05 versus Phd2+/ DOX. All graphs show mean ± SEM. See also Figure S7 and Table S7.
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Phd2 Targeting Optimizes Chemotherapytypes that overexpress Phd2 compared to their normal histo-
logical counterpart than tumor types that underexpress this
gene, thus indicating Phd2 as an oncogene more than an onco-
suppressor (Ameln et al., 2011). For this reason, simultaneous(E) 8-OHdG positive nuclei are significantly reduced in Phd2+/ hearts under a c
(F–H) Enhanced expression of antioxidative enzymes (AOE) in Phd2+/ hearts (F) a
(H; n = 3) levels.
(I) RNA levels of AOE in DOX-treated Phd2+/ mice upon administration of the R
(J) Plasma CK upon combined treatment with DOX and AOE inhibitors (n = 3–6).
(K) Treatment of WT mice with the nonspecific PHD2 inhibitor DMOG prevents t
(L) Combined administration of DMOG and DOX strongly upregulates AOE trans
Unless otherwise denoted: *p < 0.05 versus WT, #p < 0.05 versus WT baseline (no
(A) and (C). All graphs show mean ± SEM. See also Figure S6 and Tables S5 andinactivation of Phd2 in both tumor stroma and cancer cells re-
mained enigmatic. Our data show that tumors generated by
Phd2 hypomorphic LLC cells still display an advantageous
response to chemotherapy when the tumor is embedded inhronic regimen of DOX (2.5 mg/kg; 33 per week; n = 4–8; *p < 0.05).
nd kidneys (G) after chemotherapy, both at the RNA (F and G; n = 6) and protein
OS scavenger MnTBAP (n = 3–5; #p < 0.05 versus WT vehicle).
he increase of plasma CK after DOX (n = 5–6).
cript levels in WT hearts (n = 5–6).
t shown) or vehicle, xp < 0.05 versus Phd2+/ DOX. Scale bars denote 20 mm in
S6.
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Figure 8. HIF-Inhibition Abrogates Chemo-
protection in Phd2+/– Mice
(A) RNA levels of AOE in WT and Phd2+/ hearts
upon combined treatment with DOX and the HIF-
inhibitor chetomin (CH; n = 6).
(B) Morphometric quantification of 8-OHdG+
nuclei, showing increased oxidative stress in
Phd2+/ mice upon combined DOX and CH
treatment (n = 5).
(C) H&E-stained heart sections show increased
myofiber disarray (dotted line) and apoptotic
features (arrow) in Phd2+/ mice after combined
treatment of DOX and CH.
(D) Acting as an oxygen-sensitive enzyme,
reduced activity of PHD2 in EC promotes tumor
vessel normalization in a HIF-2a-dependent man-
ner, thus optimizing the delivery of chemo-
therapeutic drugs to the tumor, increasing their
antitumor and antimetastatic effects (left panel).
In healthy organs, the overall prolyl hydroxylase
activity is hampered by chemotherapy-induced
reactive oxygen species (ROS), resulting in HIF-1a
and HIF-2a stabilization and subsequent tran-
scription of antioxidative defenses (Sod1, Sod2,
Cat, and Gpx1). Genetic deletion of Phd2 reduces
the threshold of HIFs activation and thus favors
this feedback loop, which promptly counters
oxidative damage and prevents organ failure and
tissue demise (right panel). Targeting PHD2 might
therefore offer a double advantage in the treatment
of oncological diseases.
*p < 0.05 versus WT, #p < 0.05 versus baseline,
xp < 0.05 versus Phd2+/ DOX. Scale bars denote
100 mm in (C). All graphs show mean ± SEM.
Cancer Cell
Phd2 Targeting Optimizes Chemotherapya Phd2-deficient environment, suggesting that systemic inhibi-
tion of PHD2 might offer beneficial effects in cancer treatment.
Further studies are needed to extend these findings to different
tumor cell types.274 Cancer Cell 22, 263–277, August 14, 2012 ª2012 Elsevier Inc.PHD2 inactivation also prevented
cardiac and renal toxicity derived by
chemotherapy-induced ROS. Inactiva-
tion of PHDs predisposes responses to
hypoxia and preconditioning stimuli (Ara-
gone´s et al., 2009; Eckle et al., 2008;
Huang et al., 2008; Hyva¨rinen et al.,
2010; Mazzone et al., 2009; Takeda
et al., 2011). Indeed, oxygen consump-
tion in hypoxia is associated with genera-
tion of ROS that peaks after tissue reoxy-
genation; stabilization of HIF-1a and/or
HIF-2a have been associated with tran-
scription of antioxidative defenses that
protect the cell from oxidative damage
(Date et al., 2005; Lee et al., 1997; Martin
et al., 2005; Mukhopadhyay et al., 2000;
Scortegagna et al., 2003). However,
when the production of ROS overwhelms
the detoxification capacity of the cell,
excessive oxidative damage leads to
cell death (Aragone´s et al., 2008; Minottiet al., 2004; Shokolenko et al., 2009; Unnikrishnan et al., 2009).
The same phenomenon occurs during treatment with doxoru-
bicin and cisplatin (Berthiaume and Wallace, 2007; Pabla and
Dong, 2008).
Cancer Cell
Phd2 Targeting Optimizes ChemotherapyThe current study suggests that an initial burst of ROS
production by chemotherapeutic drugs is required to stabilize
both HIF-1a and HIF-2a and to promote their activity in normoxic
conditions. Indeed, when ROS are increased, iron oxidation
results in the inactivation of prolyl hydroxylase activity, since
this metal is an essential cofactor for these enzymes (Gerald
et al., 2004). This feedback loop provides a built-in safety mech-
anism to diminish tissue damage. Phd2 (haplo)deficiency
decreases the threshold of HIF activation and favors the tran-
scription of antioxidative defenses that further limit the abun-
dance of ROS. A reduction of prolyl hydroxylase activity by
chemotherapy-associated ROS production will also trigger the
same detoxification program in WT organs, but less efficiently
than in Phd2 (haplo)deficient organs. In other words, by re-
ndering the organs better preadapted to oxidative stress,
(haplo)deficiency of Phd2 promptly counteracts ROS-induced
tissue damage. These findings unravel a mechanism for ROS
homeostasis by PHD2, which is independent of hypoxia, and
implies a relevance of PHD2 in other oxidative stress-related
pathophysiological conditions, suchasneurodegenerative disor-
ders, diabetes, and aging (Fraisl et al., 2009).
Our data indicate that the involvement of PHD2 in response to
chemotherapeutic drugs is highly context and cell-type depen-
dent, since Phd2 silencing in proliferating cancer cells did not
affect AOE in response to doxorubicin: neither did it modify
ROS production. However, the factors conferring cell specificity
to this response need to be defined. From a therapeutic point of
view, our findings support the idea that systemic inhibition of
PHD2 might offer chemoprotection of normal organs without
promoting chemoresistance in cancer cells.
In our previous study, we show that HIF-2a is mainly respon-
sible for Phd2+/ EC quiescence/normalization (Mazzone et al.,
2009); in this study, we show that both HIF-1a and HIF-2a are
involved in the detoxification program in Phd2+/ organs. Both
HIFs have been previously reported as upstream regulators of
an antioxidative response in different cell types (Bertout et al.,
2009; Mukhopadhyay et al., 2000; Scortegagna et al., 2003).
Genetic inactivation of Hif2a reduced the levels of Sod1, Sod2,
Cat, andGpx1 and resulted inmultiple organ failure in developing
embryos and neonates (Scortegagna et al., 2003). However,
Phd2 inactivation will lead to simultaneous accumulation of
both HIF isoforms, representing a different scenario from the
one described in previous studies, showing genetic deletion (or
silencing) of Hif1a or Hif2a (Bertout et al., 2009; Scortegagna
et al., 2003; Vengellur et al., 2003, 2011). Overall, the involvement
of HIF in favoring tumor vessel normalization and limiting the
undesired effects of chemotherapy warrants some caution for
considerate use of HIF inhibitors for cancer therapy (Semenza,
2003).
Finally, heterozygous and homozygous deletion of Phd2
comparably sensitizes the tumor to chemotherapeutic drugs
and minimizes their adverse effects. From a molecular point of
view, HIF-2a (themain driver of vessel normalization) was higher,
but equally elevated in both Phd2+/ and Phd2/ EC. This is
likely due to compensatorymechanisms inPhd2 null cells, where
Phd3 upregulation might tune down to the heterozygous levels
the genetic response triggered by complete loss of Phd2, as re-
ported during embryo development (Minamishima et al., 2009).
In cardiomyocytes, despite a dose-dependent effect of hetero-zygous versus homozygous Phd2 deletion on HIF-1a and HIF-
2a stabilization at baseline, in response to doxorubicin, both
HIFs reached their plateau in Phd2+/ and Phd2/ cells, thus
displaying a comparable antioxidative response.
To date, PHD2-specific inhibitors are not commercially avail-
able, although several screening platforms have been estab-
lished (Fraisl et al., 2009). It will be clinically relevant to validate
these drugs in mouse models of cancer in combination with
chemotherapy. At this stage, our study provides insight on
how PHD2 can regulate drug delivery to the tumor by sensing
oxygen availability and readapting vessel perfusion and can
counter the onset of chemotherapy-associated side-toxicity by
working as a gatekeeper for ROS production.
EXPERIMENTAL PROCEDURES
More detailed methods can be found in the Supplemental Information.
Syngeneic Tumor Models
106 B16F10.9 melanoma (B16) cells or 106 Lewis lung carcinoma (LLC)
cells were injected subcutaneously. Tumor volumes were measured 33 per
week with a caliper and calculated using the formula: V = p 3 [width2 3
length] / 6. At an average of 100 mm3, mice were randomized for intra-
peritoneal (i.p.) administration (2.5 mg/kg; 33 per week) of cisplatin (CPt) or
doxorubicin (DOX) in B16 or LLC tumor-bearing mice, respectively. In tumor
experiments using the Rosa26CreERT2 deleter, tamoxifen treatment (1 mg/
mouse/day i.p. for 5 consecutive days) was started on the day of cancer cell
injection. Housing and all experimental animal procedures were approved by
the Institutional Animal Care and Research Advisory Committee of the KU
Leuven.
Cisplatin Quantification
The CPt in B16 tumors was quantified by inductively coupled plasma mass
spectrometry (ICP820-MS, Varian, USA) or by immunohistochemical staining
against CPt DNA-adducts (NKI-159; a gift of Dr. B. Floot, Netherlands Cancer
Institute).
Tumor Interstitial Fluid Pressure
Tumor interstitial fluid pressure was evaluated in the central cystic tumor area
of subcutaneous LLC tumors using the ‘‘wick-in-needle’’ technique (Hofmann
et al., 2006).
Acute or Chronic Doxorubicin Cardiotoxicity
Tumor-free mice were injected with a single dose of 20 mg/kg DOX (i.p.) and
assessed for cardiotoxicity after 5 days or with 2.5mg/kgDOX (i.p.) three times
a week for a total of 4 weeks, respectively.
Acute or Chronic Cisplatin Nephrotoxicity
Tumor-free mice were injected with a single dose of 20 mg/kg CPt (i.p.) and
assessed for renal toxicity after 3 days or with 2.5 mg/kg CPt (i.p.) three times
a week for a total of 4 weeks, respectively.
HIF Activity In Vivo
The adenovirus-associated virus 9 (AAV9) HIF reporter plasmid (AAV9-HRE-
LUC) contains a minimal promoter fused to 9 copies of hypoxia-responsive
elements (HRE) followed by the firefly luciferase (LUC)(Aragone´s et al., 2001)
in pSubCMV-WPRE (Paterna et al., 2000). AAV9 particles were generated
as previously described (Anisimov et al., 2009). A dose of 0.25 3 1011 viral
genomic copies of AAV9-HRE-LUC or the control AAV9-CMV-LUC were in-
jected in the tail vein 3 days before administration of 20 mg/kg DOX or CPt.
Immunoblot and Immunochemistry
Protein extraction was performed using RIPA (50 mM Tris HCl pH 8, 150 mM
NaCl, 1% Triton X-100, 0.1%SDS, 0.5% sodium deoxycolate). All methods for
histology and immunostainings have been described before (Mazzone et al.,
2009).Cancer Cell 22, 263–277, August 14, 2012 ª2012 Elsevier Inc. 275
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Quantitative RT-PCR (QRT-PCR) was performed as described (Fischer
et al., 2007). The Assay ID (Applied Biosystems) or the sequence of primers
and probes (when homemade) are listed in the Supplement Experimental
Procedures.
Hypoxia and Tumor Perfusion
Tumor hypoxia was detected as before (Mazzone et al., 2009). Tumor perfu-
sion was assessed by injecting intravenously 0.05 mg lectin-FITC (Lycopersi-
con esculentum; Vector Laboratories) or 5 mg high molecular weight (2 MDa)
dextran-FITC (Sigma).
Statistics
Data represent mean ± SEM of representative experiments. Statistical signif-
icance was calculated by a two-tailed unpaired t test for two data sets and
ANOVA followed by a Bonferroni post hoc test for multiple data sets using
Prism (GraphPad, Inc.), with p < 0.05 considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, seven tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2012.06.028.
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